About
Who We Are
Leadership Team
Board of Directors
Clinical and Scientific Advisors
Contact
Science
Immune Continuum
CCR4 in Inflammation
CCR4 in Cancer
Publications
Pipeline
Snapshot
Tivumecirnon (FLX475)
Discovery Programs
Investors
Corporate Profile
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Email Alerts
Investor Contact
Investor FAQs
Careers
Culture
Benefits
Open Positions
PRESS RELEASES
Year
2024
2023
2022
2021
2020
Filter
December 21 | 2017
FLX Bio Completes $60 Million Series C Financing
November 27 | 2017
FLX Bio to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
September 21 | 2017
FLX Bio Selects Immuno-Oncology Clinical Candidate
May 31 | 2017
FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board
March 31 | 2017
FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4
You are leaving RAPT.com to go to the eczema clinical trial study site.
